ArticleThe Journal of infectious diseases2025
Revealing the Unseen: Next-Generation Sequencing for Early Detection of Drug-Resistant Cytomegalovirus Variants Upon Letermovir Prophylaxis Failure.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Surveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis.Journal of medical virology · 2026Article
- Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In recipients of allogeneic hematopoietic cell transplant, prophylactic management strategies are essential for preventing cytomegalovirus (CMV) reactivation and associated disease. We report on a 63-year-old male patient with a D-/R+ CMV serostatus, who showed ongoing low-level CMV replication after hematopoietic cell transplant despite receiving letermovir prophylaxis. Sanger sequencing failed to detect drug resistance mutations (DRMs) until CMV pneumonitis developed, revealing a UL56-C325R DRM linked to high-level letermovir resistance. Retrospective analysis with next-generation sequencing revealed the DRM at a low frequency of 6% two weeks prior to detection by Sanger sequencing. This study highlights the importance of advanced next-generation sequencing methods for early detection of CMV DRMs, allowing for faster adjustments in antiviral treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.